LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) has expanded its cancer treatment capabilities through the acquisition of Liora Technologies, a company pioneering proton therapy systems for treating various types of cancers. The acquisition includes Liora's proprietary LiGHT System (Linac for Image Guided Hadron Therapy), which offers multiple advantages over existing proton therapy technologies according to industry experts.
Professor Steve Myers, former Director of Accelerators and Technology at CERN, emphasized the system's capabilities, stating that the highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. Beyond the unique biological effects, the technology is expected to significantly reduce installation costs and the number of treatment sessions needed compared to current technologies. This efficiency improvement could substantially increase the number of patients that treatment centers can serve, potentially expanding access to advanced cancer care.
The acquisition comes as LIXTE continues to advance its clinical-stage pharmaceutical development focused on new targets for cancer drug development. The company has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has shown potential to significantly enhance chemotherapies and immunotherapies while improving outcomes for cancer patients.
LIXTE's approach represents a pioneering effort in an entirely new field of cancer biology called activation lethality, which is advancing a new treatment paradigm. The company's comprehensive patent portfolio covers this innovative approach, with proof-of-concept clinical trials currently in progress for ovarian clear cell carcinoma and metastatic colon cancer. Additional information about LIXTE's developments is available through the company's newsroom at https://ibn.fm/LIXT.
The integration of Liora's proton therapy technology into LIXTE's pipeline creates a more comprehensive approach to cancer treatment, combining pharmaceutical development with advanced radiation therapy systems. This strategic move positions LIXTE to address multiple aspects of cancer care, potentially offering patients more integrated treatment options. The LiGHT System's ability to deliver precise, high-dose radiation to deep-seated tumors while reducing treatment sessions could transform how certain cancers are managed, particularly those requiring targeted radiation approaches.
For investors and industry observers seeking detailed information about the acquisition, the full article discussing the strategic move can be accessed at https://ibn.fm/W6gD5. The acquisition represents a significant step in LIXTE's growth strategy, combining pharmaceutical innovation with advanced medical device technology to create a more robust cancer treatment platform. As healthcare systems worldwide seek more effective and efficient cancer treatments, developments like the LiGHT System acquisition could influence treatment protocols and patient care standards across the oncology field.
